Professor Saad Shakir, director of the Drug Safety Research Unit looks at observational research in the UK and why it's one of the nation's core strengths.
The role of observational research, carried out after drugs have been approved for use in the general population, has come to the fore in the wake of Covid-19, when new vaccines and treatments needed to be fast-tracked through research and development to save lives.